BY MARKETWIRE
-
Future of TV Briefing: How TV networks’ streaming and linear ad businesses fared in Q4 2024
Today’s Future of television Instruction considers what television network proprietors’ newest quarterly revenues records show regarding the state of the television and…
-
Novo Nordisk stock halved since peak: Lost USD 336bn in market capitalization
The Novo Nordisk share cost came to a head at the end of June in 2015.
-
Abbvie will test monthly dose of Gubra’s weight-loss candidate
Abbvie’s head of research study claims the business is open to various other alternatives in weight problems therapies.
-
Ambu could be heading into a year of billion-kroner acquisitions
Nordea estimates that the Danish medtech group can easily set aside DKK 5bn this year for acquisitions without unnecessary strain on the balance sheet,
-
Novo Nordisk EVP pleased with new obesity data despite price drop
Experts are let down with the outcomes of a research study of the firm’s excessive weight medication prospect Cagrisema for numerous factors.
-
Lundbeck drug awarded special status in Japan
Amlenetug can probably be used to deal with the uncommon neurological illness a number of system atropophy (MSA).
-
GN’s share continues to be tossed around by uncertainty – tariff war plays a big role
The listening devices maker’s share is still without a doubt one of the most shorted Danish show simply over 9.8% of shares offered for brief marketing according to the most …
-
Gubra’s share value grew almost USD 200m on new obesity deal
Nonetheless, the rise in worth slowed down by closing time on the inventory alternate after reaching 25% at one level.
-
FDA approves ALK tablet for treatment of dust mite allergy in young children
The business has actually gotten comparable authorization in Canada.
-
Genmab’s moment of truth nears: Jyske Bank sees potential for big price reaction
Genmab will certainly quickly learn if its companion Johnson & Johnson selects to proceed working with the medication prospect Hexabody-CD38– a possible follower to sign…